Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 330
Summary
- Conditions
- Breast Cancer
- Breast Neoplasms
- Early Stage Breast Cancer
- HER2 Positive Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04109391
- Collaborators
- Not Provided
- Investigators
- Study Director: Bonnie Mills, PhD Tanvex BioPharma USA, Inc.
Get Well Soon